This Is Why I’d Sell RSA Insurance Group plc Today

RSA Insurance Group plc (LON:RSA) is a sell, says Roland Head, who believes the insurer’s shares remain overpriced.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

What do you call a company that’s cut its dividend by 33%, issued a profit warning, and accepted the resignation of its Ireland chief executive on suspicion of accounting irregularities, all in the space of 12 months?

In this case, the answer is RSA Insurance Group (LSE: RSA) (NASDAQOTH: RSANY.US), a firm whose share price has declined by 19% so far this year — so much so that its prospective dividend yield has risen above 6% once more, despite the cuts to its payout.

The resignation of RSA Ireland CEO Philip Smith following allegations of accounting irregularities is the latest below to shareholders, and the episode is expected to cost the firm £70m in lost operating profits.

Indeed, over the last five years, RSA investors have seen the value of their shares fall by 29% — compared to a 61% gain for the FTSE 100, and a 17% gain for RSA’s UK peer Aviva.

Despite all of this, short term bad news, such as RSA’s recent weather-induced profit warning, isn’t necessarily a reason to sell a stock. Indeed, it can be a good buying opportunity — so why do I rate RSA shares as a sell?

Just not cheap enough

RSA’s net asset value per share was 99p at the start of November, down from 103p in August and 107p at the end of last year.  None of these figures include RSA’s pension deficit, which was valued at £442m in July — a sum which equates to 12p a share. RSA has agreed to reduce this deficit with additional payments of between £60m and £70m per year until 2016, placing more pressure on its profits.

Given RSA’s patchy track record, I wouldn’t buy the insurer’s shares today unless they traded at a discount to their net asset value — and given this year’s slide in net asset value, I’d want a decent margin of safety, too, in case the fall continues.

In my view, RSA would be good value at around 95p, which would place them on a 2013 forecast P/E of 12, still a considerable premium to Aviva, whose shares currently trade on a 2013 forecast P/E of 9.7.

A better buy for income?

RSA enjoyed a strong reputation with income investors who believed its dividend wouldn’t be cut. That belief is now history and with limited cash flow to cover the firm’s dividend payout, a further cut isn’t impossible.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

 > Roland owns shares in Aviva, but does not own shares in RSA Insurance Group.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »